Hopes that antiretroviral drugs might prove useful against COVID-19 were decreased with the results of a trial reported in the New England Journal of Medicine, March 18.
Researchers in China examined the effect of a lopinavir/ritonavir mix in roughly half of 199 COVID-19 patients with advanced disease. The drugs didn’t affect the length of time it took to undergo clinical improvement, nor did they have any influence on the rate of death.
The researchers who conducted the study suggest that additional testing may be justified in patients with less advanced disease. For now, though, these statistics indicate that the lopinavir/ritonavir combination doesn’t help treat a COVID disease.